%0 Journal Article
%T Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in Guinea
%A Achille Guemou
%A Alexandre Delamou
%A Almudena Mari-Saez
%A Anja De Weggheleire
%A Bienvenu Salim Camara
%A Chantal Jacquot
%A Jan Jacobs
%A Jean Pe Kolie
%A Johan van Griensven
%A Kadio Jean-Jacques Olivier Kadio
%A Lutgarde Lynen
%A Maaike De Crop
%A Maya Ronse
%A Nyankoye Yves Haba
%A Patricia Chavarin
%A Pierre Gallian
%A for the Ebola-Tx Consortium
%J Archive of "The American Journal of Tropical Medicine and Hygiene".
%D 2016
%R 10.4269/ajtmh.15-0890
%X Although convalescent plasma (CP) transfusion was prioritized among potential Ebola treatments by the World Health Organization, there were concerns on the feasibility of its implementation. We report on the successful organization of donor mobilization and plasma collection as part of the Ebola-Tx clinical trial from November 2014 to July 2015 in Conakry, Guinea. Project implementation registers, tools and reports, mission reports, and minutes of research team meetings were used to reconstruct the sequence of events on how donor mobilization was organized, plasmapheresis was set up, and how effective this approach was in collecting CP. An initial needs assessment of the Guinean National Blood Transfusion Center resulted in targeted training of staff on site, resulting in autonomy and independent production of CP within 3 months. The Conakry Ebola Survivors Association played a direct role in donor mobilization and organization of CP donations. A total of 98 Ebola survivors were screened for plasma donation, of which 84 were found eligible for plasmapheresis. Of these, 26 (30.9%) were excluded. The remaining 58 donors made a total of 90 donations, corresponding to 50.9 L of CP. This sufficed to treat the 99 eligible patients enrolled in the trial. Within a poor resource emergency context, transfusion capacity could be rapidly improved through the strengthening of local capacities and gradual transfer of skills coupled with active involvement of Ebola survivors. However, large-scale plasma collection or multisite studies may require further adaptations of both strategy and logistics. The Ebola-Tx trial was funded by the European Union and others
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014273/